Therapeutic strategies for the prevention and treatment of cytomegalovirus infection

Expert Opinion on Biological Therapy

Volumn 12, Issue 9, 2012, Pages 1161-1172

  Sellar, Rob S ^a   Peggs, Karl S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cellular therapy; Cytomegalovirus; Immune response; Transplantation

Indexed keywords

ACICLOVIR; ARTESUNATE; BENZIMIDAVIR; CELL PRODUCT; CELL PROTEIN; CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; DNA VACCINE; GAMMA INTERFERON; GANCICLOVIR; IMMUNOGLOBULIN; LEFLUNOMIDE; LETERMOVIR; PLACEBO; TETRAMER; UNCLASSIFIED DRUG; VALACICLOVIR; VALGANCICLOVIR;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE T CELL THERAPY; ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ANTIVIRAL ACTIVITY; BACTERIAL INFECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL THERAPY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOMEGALOVIRUS PNEUMONITIS; DIARRHEA; DISEASE SEVERITY; DRUG TREATMENT FAILURE; GENETIC ENGINEERING; GOOD MANUFACTURING PRACTICE; GRAFT VERSUS HOST REACTION; HLA TYPING; HUMAN; IMMUNE RESPONSE; IMMUNOPROPHYLAXIS; LIVER FUNCTION TEST; MEDLINE; MULTIDRUG RESISTANCE; NEUTROPENIA; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; T LYMPHOCYTE; VIREMIA; VIRUS IMMUNITY; VIRUS LOAD; VIRUS MUTATION; VIRUS PNEUMONIA; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ADOPTIVE TRANSFER; ANIMALS; ANTIVIRAL AGENTS; BIOTECHNOLOGY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, MULTIPLE, VIRAL; HUMANS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84865324427     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.693471     Document Type: Review

References (74)

1. Sester M, Sester U, Gartner B, et al. Sustained high frequencies of specific CD4 T cells restricted to a single persistent virus. J Virol 2002;76:3748-55 (Pubitemid 34250539)
2. Khan N, Shariff N, Cobbold M, et al. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol 2002;169:1984-92 (Pubitemid 34857662)
3. Pourgheysari B, Khan N, Best D, et al. The cytomegalovirus-specific CD4+ T-cell response expands with age and markedly alters the CD4+ T-cell repertoire. J Virol 2007;81:7759-65 (Pubitemid 47047862)
4. Elkington R, Walker S, Crough T, et al. Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol 2003;77:5226-40 (Pubitemid 36460937)
5. Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005;202:673-85 (Pubitemid 41248418)
6. Pawelec G, Derhovanessian E, Larbi A, et al. Cytomegalovirus and human immunosenescence. Rev Med Virol 2009;19:47-56
7. Khan N, Hislop A, Gudgeon N, et al. Herpesvirus-specific CD8 T cell immunity in old age: cytomegalovirus impairs the response to a coresident EBV infection. J Immunol 2004;173:7481-9 (Pubitemid 39628188)
8. Boeckh M, Nichols WG, Papanicolaou G, et al. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003;9:543-58 (Pubitemid 38351787)
9. Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003;101:407-14 (Pubitemid 36077556)
10. Broers AE, van Der Holt R, van Esser JW, et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 2000;95:2240-5 (Pubitemid 30167720)
11. Cortelezzi A, Pasquini MC, Gardellini A, et al. Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. Leukemia 2009;23:2027-33
12. Cwynarski K, Ainsworth J, Cobbold M, et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 2001;97:1232-40 (Pubitemid 32183744)
13. Aubert G, Hassan-Walker AF, Madrigal JA, et al. Cytomegalovirus-specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants. J Infect Dis 2001;184:955-63 (Pubitemid 32955111)
14. Gratama JW, van Esser JW, Lamers CH, et al. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 2001;98:1358-64
15. Hebart H, Daginik S, Stevanovic S, et al. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood 2002;99:3830-7 (Pubitemid 34534558)
16. Pergam SA, Xie H, Sandhu R, et al. Efficiency and Risk Factors for CMV Transmission in Seronegative Hematopoietic Stem Cell Recipients. Biol Blood Marrow Transplant 2012 Mar 3. [Epub ahead of print]
17. Wloch MK, Smith LR, Boutsaboualoy S, et al. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis 2008;197:1634-42 (Pubitemid 351919626)
18. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009;15:1143-238
19. Raanani P, Gafter-Gvili A, Paul M, et al. Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis. J Clin Oncol 2009;27:770-81
20. Meyers JD, Reed EC, Shepp DH, et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 1988;318:70-5 (Pubitemid 18029297)
21. Prentice HG, Gluckman E, Powles RL, et al. Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. the European Acyclovir for CMV prophylaxis study group. Bone Marrow Transplant 1997;19:129-33 (Pubitemid 27068248)
22. Ljungman P, de La Camara R, Milpied N, et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 2002;99:3050-6 (Pubitemid 34525398)
23. Goodrich JM, Bowden RA, Fisher L, et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993;118:173-8 (Pubitemid 23034801)
24. Winston DJ, Young JA, Pullarkat V, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 2008;111:5403-10
25. Marty FM, Ljungman P, Papanicolaou GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 2011;11:284-92
26. Biron KK, Stanat SC, Sorrell JB, et al. Metabolic activation of the nucleoside analog 9-[(2-hydroxy-1-(hydroxymethyl) ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Natl Acad Sci USA 1985;82:2473-7 (Pubitemid 15071291)
27. Einsele H, Reusser P, Bornhauser M, et al. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood 2006;107:3002-8
28. Gerna G, Lilleri D, Zecca M, et al. Rising antigenemia levels may be misleading in pre-emptive therapy of human cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. Haematologica 2005;90:526-33 (Pubitemid 40592896)
29. Nichols WG, Corey L, Gooley T, et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood 2001;97:867-74 (Pubitemid 32154267)
30. Foulongne V, Turriere C, Diafouka F, et al. Ganciclovir resistance mutations in UL97 and UL54 genes of human cytomegalovirus isolates resistant to ganciclovir. Acta Virol 2004;48:51-5
31. Marfori JE, Exner MM, Marousek GI, et al. Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. J Clin Virol 2007;38:120-5 (Pubitemid 46074451)
32. van der Beek MT, Berger SP, Vossen AC, et al. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance. Transplantation 2010;89:320-6
33. Reusser P, Einsele H, Lee J, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002;99:1159-64 (Pubitemid 34547067)
34. Scott GM, Weinberg A, Rawlinson WD, et al. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob Agents Chemother 2007;51:89-94 (Pubitemid 46047692)
35. Sellar RS, Peggs KS. Management of multidrug-resistant viruses in the immunocompromised host. Br J Haematol 2012;156:559-72
36. Avery RK, Marty FM, Strasfeld L, et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis 2010;12:489-96
37. Strasfeld L, Lee I, Tatarowicz W, et al. Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir. J Infect Dis 2010;202:104-8
38. Avery RK, Bolwell BJ, Yen-Lieberman B, et al. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection. Bone Marrow Transplant 2004;34:1071-5 (Pubitemid 40028840)
39. Avery RK, Mossad SB, Poggio E, et al. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation 2010;90:419-26
40. John GT, Manivannan J, Chandy S, et al. A prospective evaluation of leflunomide therapy for cytomegalovirus disease in renal transplant recipients. Transplant Proc 2005;37:4303-5 (Pubitemid 43016014)
41. Quenelle DC, Lampert B, Collins DJ, et al. Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies. J Infect Dis 2010;202:1492-9
42. Wan WB, Beadle JR, Hartline C, et al. Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro. Antimicrob Agents Chemother 2005;49:656-62 (Pubitemid 40175677)
43. Ciesla SL, Trahan J, Wan WB, et al. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res 2003;59:163-71 (Pubitemid 36966748)
44. Lischka P, Hewlett G, Wunberg T, et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother 2010;54:1290-7
45. Goldner T, Hewlett G, Ettischer N, et al. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol 2011;85:10884-93
46. Kaul DR, Stoelben S, Cober E, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant 2011;11:1079-84
47. Adjuik M, Babiker A, Garner P, et al. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 2004;363:9-17 (Pubitemid 38076919)
48. Efferth T, Marschall M, Wang X, et al. Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses. J Mol Med (Berl) 2002;80:233-42 (Pubitemid 34439295)
49. Kaptein SJ, Efferth T, Leis M, et al. The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo. Antiviral Res 2006;69:60-9 (Pubitemid 43152041)
50. Shapira MY, Resnick IB, Chou S, et al. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis 2008;46:1455-7 (Pubitemid 351589951)
51. Lau PK, Woods ML, Ratanjee SK, et al. Artesunate is ineffective in controlling valganciclovir-resistant cytomegalovirus infection. Clin Infect Dis 2011;52:279
52. Wolf DG, Shimoni A, Resnick IB, et al. Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation. Antiviral Res 2011;90:183-6
53. Peggs KS. Adoptive T cell immunotherapy for cytomegalovirus. Expert Opin Biol Ther 2009;9:725-36
54. Fujita Y, Rooney CM, Heslop HE. Adoptive cellular immunotherapy for viral diseases. Bone Marrow Transplant 2008;41:193-8 (Pubitemid 351188917)
55. Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003;362:1375-7 (Pubitemid 37338339)
56. Peggs KS, Verfuerth S, Pizzey A, et al. Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation. Clin Infect Dis 2009;49:1851-60
57. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038-44
58. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002;99:3916-22 (Pubitemid 35332029)
59. Micklethwaite K, Hansen A, Foster A, et al. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007;13:707-14 (Pubitemid 46767999)
60. Cobbold M, Khan N, Pourgheysari B, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005;202:379-86 (Pubitemid 41126955)
61. Yao J, Bechter C, Wiesneth M, et al. Multimer staining of cytomegalovirus phosphoprotein 65-specific T cells for diagnosis and therapeutic purposes: a comparative study. Clin Infect Dis 2008;46:e96-105
62. Schmitt A, Tonn T, Busch DH, et al. Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion 2011;51:591-9
63. Feuchtinger T, Opherk K, Bethge WA, et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 2010;116:4360-7
64. Peggs KS, Thomson K, Samuel E, et al. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis 2011;52:49-57
65. Zandvliet ML, van Liempt E, Jedema I, et al. Co-ordinated isolation of CD8(+) and CD4(+) T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy. Cytotherapy 2010;12:933-44
66. Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006;12:1160-6 (Pubitemid 44527351)
67. Gerdemann U, Vera JF, Rooney CM, et al. Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant. J Vis Exp 2011;51
68. Zandvliet ML, van Liempt E, Jedema I, et al. Simultaneous isolation of CD8(+) and CD4(+) T cells specific for multiple viruses for broad antiviral immune reconstitution after allogeneic stem cell transplantation. J Immunother 2011;34:307-19
69. Lugthart G, Albon SJ, Ricciardelli I, et al. Simultaneous generation of multivirus-specific and regulatory T cells for adoptive immunotherapy. J Immunother 2012;35:42-53
70. Khanna N, Stuehler C, Conrad B, et al. Generation of a multipathogen-specific T-cell product for adoptive immunotherapy based on activation-dependent expression of CD154. Blood 2011;118:1121-31
71. Hanley PJ, Cruz CR, Savoldo B, et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 2009;114:1958-67
72. Hanley PJ, Martinez C, Leung K, et al. Phase I study to improve virus-specific immune reconstitution after cord blood transplantation using cord blood-derived virus-specific cytotoxic T lymphocytes. ASH Annual Meeting Abstracts 2011;118:155
73. Schub A, Schuster IG, Hammerschmidt W, et al. CMV-specific TCR-transgenic T cells for immunotherapy. J Immunol 2009;183:6819-30
74. Full F, Lehner M, Thonn V, et al. T cells engineered with a cytomegalovirus-specific chimeric immunoreceptor. J Virol 2010;84:4083-8